SINOPHARM (01099) released its annual performance, with a net profit attributable to the parent company of 7.155 billion yuan, a year-on-year increase of 1.5%. The final dividend is 0.69 yuan per share.

Sinopharm (01099) released its annual performance up to December 31, 2025. The group achieved a revenue of RMB 575.168 billion, a decrease of 1.6% year-on-year; the net profit attributable to owners of the parent company was RMB 7.155 billion, an increase of 1.5% year-on-year; earnings per share were RMB 2.29, with a proposed final dividend of RMB 0.69 per share. In terms of operational efficiency improvement, the group focused on scale effects and cost leadership strategies, promoting cost reduction and lean management. By the end of 2025, the group's overall expense ratio decreased by 0.25 percentage points year-on-year, effectively offsetting the decrease in gross profit. During the reporting period, operating cash flow achieved a net inflow of RMB 14.138 billion, an increase of RMB 2.592 billion compared to the same period last year, highlighting the effectiveness of cash flow management; the growth rate of accounts receivable significantly narrowed, and the specific management of accounts receivable showed results; the asset-liability ratio decreased by 2.12 percentage points year-on-year. With the improvement in internal governance efficiency, the group effectively resisted market fluctuations, achieving a 0.02 percentage point increase in operating profit margin year-on-year, demonstrating strong risk resilience and development resilience overall, laying a solid foundation for a successful conclusion to the "Fourteenth Five-Year Plan" and strategic planning for the "Fifteenth Five-Year Plan." In 2025, the group's primary task is to focus on high-quality development, scientifically assess the market trends and competitive landscape in various regions, actively expand market share, and drive quality and efficiency improvement through reform and innovation. During the reporting period, the three major business segments continued to show differentiated development trends. Among them, the revenue contribution from the pharmaceutical distribution segment reached 72.79%, a decrease of 0.37 percentage points year-on-year; the revenue contribution from the medical equipment distribution segment reached 19.32%, a slight decrease of 0.09 percentage points year-on-year; the revenue contribution from the pharmaceutical retail segment reached 6.42%, an increase of 0.50 percentage points year-on-year.